HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi Japan to Sharpen Focus on Priority Pipelines as It Eyes Turnaround after 2022: President
December 1, 2020
-
BUSINESS Demand for Nesp Biosimilars Spiking as Hospitals Turn to Cheaper Meds in Dialysis Care, Shipment Control Triggered
December 1, 2020
-
REGULATORY MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
-
REGULATORY Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
-
REGULATORY LDP Health Policy Clique Set to Urge Govt to Skip Off-Year Re-Pricing Next Year, but Explore Middle Ground at Same Time
November 27, 2020
-
REGULATORY MOF Panel Issues FY2021 Budget Recommendation, Ups Tone on All-Product Drug Re-Pricing
November 26, 2020
-
REGULATORY 3 Pharma Groups: Limit Scope of Off-Year Re-Pricing to Drugs with “Significantly Large Discrepancy Rates”
November 26, 2020
-
REGULATORY MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
-
REGULATORY Ryukaikon Confab Held after 17 Month Hiatus, COVID-19 Impact on Drug Distribution Discussed
November 25, 2020
-
ACADEMIA Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
-
BUSINESS Improved Hygiene amid COVID-19 Hit Infectious Disease Meds, Big-Seller Hopefuls See Slow Uptake
November 24, 2020
-
REGULATORY 1st Humira Biosimilar to Join NHI Price List on Nov. 25
November 24, 2020
-
BUSINESS Big 3 Generic Makers Log 7.2% Growth in 1st Half, Suffer Sluggish Japan Sales on Price Cuts, COVID-19: Jiho Tally
November 20, 2020
-
ORGANIZATION EFPIA Japan Chief Frets Declining Priority for Japan Market since 2018 Pricing Overhaul
November 19, 2020
-
ACADEMIA National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
November 18, 2020
-
REGULATORY Drug Makers Disclosing as Much Cost Info as Possible in Price Negotiations, JPMA Chief Rebuts Concerns Aired in Project Review
November 17, 2020
-
REGULATORY With Consensus on 13 Topics Delayed by COVID-19, ICH Expected to Restrict Selection of New Topics at Virtual Assembly
November 16, 2020
-
REGULATORY “No Comment with Prejudgment” on COVID-19 Shots for Children: Minister
November 16, 2020
-
BUSINESS Generic Makers Seeking to Invalidate Feburic Patent, Can They Get Full Indications?
November 13, 2020
-
BUSINESS New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
November 12, 2020
ページ
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…